Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ Origin: Appendix 5 \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13$ 

Baby Bunting Group Limited ("Company")

#### ABN

58 128 533 693

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- <sup>+</sup>Class of <sup>+</sup>securities issued or to be issued
- (a) Fully paid ordinary shares (quoted)
- (b) performance rights (unquoted)
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- (a) 938,103 ordinary shares
- (b) 2,311,000 performance rights
- **Principal** of the terms 3 +securities (e.g. if options, exercise price and expiry date; if \*securities, partly paid the amount outstanding and due dates for payment; if +convertible securities. the conversion price and dates for conversion)
- (a) Fully paid ordinary shares
- (b) Performance rights are granted subject to the terms and conditions of the Company's Long Term Incentive Plan. The terms applying to the grant of performance rights are described in the Company's 2019 Notice of AGM.

04/03/2013 Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

Do the \*securities rank equally in all respects from the +issue date with an existing +class of auoted +securities?

> If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a distribution) interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- Issue price or consideration 5

Purpose of the issue

identify those assets)

6

(b) Nil

- (a) Yes
- (b) See above.

- (a) No amount was payable by recipients of the shares. Shares were issued at \$3.62 per share.
- (If issued as consideration for the acquisition of assets, clearly

#### (a) Shares issued upon vesting of TSR performance rights

938,103 shares were issued in satisfaction of performance rights that have vested and been exercised. These shares have been issued to the Company's CEO and Managing Director and other participating executives.

These performance rights were granted pursuant to the Company's Long Term Incentive Plan established at the time of the Company's IPO in October 2015. (Details of the rights and the plan are set out in the 2019 Remuneration Report).

The performance rights that vested were assessed against the total shareholder return (TSR) performance condition. compound annual growth rate of TSR as measured from listing in October 2015 (share price \$1.40) to the volume weighted average share price in the period 1 July 2019 to 30 September 2019 (inclusive) (including

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

		dividends taken to be reinvested) was 24.3%. Accordingly, 94.3% of the share rights to be tested at this point, vested and were available to be exercised.	
		(b) Grant of performance rights	
		Grant of performance rights pursuant to the Company's Long Term Incentive Plan.	
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	No	
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i		
6b	The date the security holder resolution under rule 7.1A was passed		
6с	Number of *securities issued without security holder approval under rule 7.1		
6d	Number of *securities issued with security holder approval under rule 7.1A		
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)		
6f	Number of *securities issued under an exception in rule 7.2		
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.		

o4/o3/2013 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

- 6h If \*securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A complete Annexure 1 and release to ASX Market Announcements
- 7 \*Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

- (a) 25 October 2019
- (b) 25 October 2019
- 8 Number and \*class of all \*securities quoted on ASX (including the \*securities in section 2 if applicable)

Number	<sup>+</sup> Class
127,564,474	Fully paid ordinary shares

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class	
10,148,454	Rights granted	
	pursuant to the	
The above figure	Company's Long	
comprises:	Term Incentive Plan	
(a) 4,519,454 performance rights to be tested after the conclusion of FY2020 (a reduction of 938,103 from the amount previously disclosed due to vesting of rights)		
(b) 2,704,000 performance rights to be tested after the conclusion of FY2021 (no change)  (c) 614,000 retention rights (no change)		

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

		(d) 2,311,000 performance rights to be tested after the conclusion of FY2022 (new)
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	(a) The new shares rank equally with existing shares
	1 ( /	(b) Not applicable
Part :	2 - Pro rata issue	
11	Is security holder approval	
	required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

04/03/2013 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B New issue announcement

20	Names of any underwriters	
21	Amount of any underwriting fee	
	or commission	
22	Names of any brokers to the	
22	issue	
	Francisco de la la de de la la de	
23	Fee or commission payable to the broker to the issue	
	5.5.16.1 65 61.6 155.46	
24	Amount of any handling fee	
	payable to brokers who lodge	
	acceptances or renunciations on behalf of security holders	
	benan of security noiders	
25	If the issue is contingent on	
	security holders' approval, the	
	date of the meeting	
26	Date entitlement and acceptance	
20	form and offer documents will be	
	sent to persons entitled	
27	If the entity has issued options,	
	and the terms entitle option holders to participate on	
	exercise, the date on which	
	notices will be sent to option	
	holders	
28	Date rights trading will begin (if	
20	applicable)	
29	Date rights trading will end (if	
	applicable)	
30	How do security holders sell	
	their entitlements <i>in full</i> through a broker?	
	a DIOKET!	
31	How do security holders sell <i>part</i>	
,	of their entitlements through a	
	broker and accept for the	
	balance?	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	
33	⁺Issu€	e date	
		uotation of securitie	
34	Type (tick o	of *securities one)	
(a)		<sup>+</sup> Securities described in Part	1
(b)			nd of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible
Entiti	es tha	t have ticked box 34(a)	
Addit	tional	securities forming a new	class of securities
Tick to docum		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities
36			securities, a distribution schedule of the additional amber of holders in the categories
37		A copy of any trust deed for	the additional <sup>+</sup> securities
Entiti	es tha	t have ticked box 34(b)	
38		per of <sup>+</sup> securities for which ation is sought	

o4/o3/2013 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.

39	*Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	<sup>+</sup> Class

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 25 October 2019

(Company secretary)

Print name: Corey Lewis

== == == == ==

04/03/2013 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.